共 86 条
[1]
Simpson DM(2016)Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology Neurology 86 1818-1826
[2]
Hallett M(2019)Immunogenicity associated with botulinum toxin treatment Toxins 11 491-506
[3]
Ashman EJ(2019)Reply to comment on re-visiting immunogenicity associated with botulinum toxin reatment Toxins 11 491-e54
[4]
Bellows S(2019)Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia Ther Adv Neurol Disord 12 1756286419892078-274
[5]
Jankovic J(2016)High botulinum toxin-neutralizing antibody prevalence under long-term cervical dystonia treatment Mov Disord Clin Pract 3 500-597
[6]
Bellows S(2019)High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy Neurology 92 e48-1360
[7]
Jankovic J(1999)Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency J Neurol 246 265-136
[8]
Hefter H(2005)Long-term botulinum toxin efficacy, safety, and immunogenicity Mov Disord 20 592-218
[9]
Rosenthal D(2008)Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay Mov Disord Off J Mov Disord Soc 23 1353-117
[10]
Bigalke H(2008)Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A Neurology 70 133-247